Your email has been successfully added to our mailing list.

×
-0.0101010101010101 -0.0070707070707071 -0.0414141414141414 -0.0404040404040404 -0.0202020202020201 -0.0227272727272727 -0.0226414141414141 -0.0404040404040404
Stock impact report

Lyra Therapeutics raises $56 million in IPO, priced at high end of range [MarketWatch]

Lyra Therapeutics, Inc. (LYRA) 
Company Research Source: MarketWatch
Lyra Therapeutics Inc. , a biotech specializing in treatments for ear, nose and throat diseases, priced its initial public offering late Thursday at $16 a share, the high end of its price range. The company sold 3.5 million shares to raise $56 million. BofA, Jefferies, William Blair and BTIG are underwriters on the deal. Proceeds will be used to fund clinical trials, for R&D and for platform development, working capital and other general corporate purposes. The stock will start trading on Nasdaq later Friday, under the ticker symbol "LYRA." Show less Read more
Impact Snapshot
Event Time:
LYRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for LYRA alerts
Opt-in for
LYRA alerts

from News Quantified
Opt-in for
LYRA alerts

from News Quantified